Briefing
DYNAMIC-III: ctDNA that remained positive after treatment marked a much higher recurrence risk
In the same DYNAMIC-III analysis published in Nature Medicine on October 20, 2025, patients with stage III colon cancer whose ctDNA stayed positive after treatment had a 3-year recurrence-free survival of 14%, compared with 79% among patients who cleared ctDNA.